(Q53807444)

20 May 2018

title

Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. (English)

1 reference

20 May 2018

11

Federico Garrido

1 reference

20 May 2018

author name string

Francisco Javier Carretero

1

1 reference

20 May 2018

Ana Belen Del Campo

2

1 reference

20 May 2018

Jose Francisco Flores-Martín

3

1 reference

20 May 2018

Rosa Mendez

4

1 reference

20 May 2018

Cesar García-Lopez

5

1 reference

20 May 2018

Jose Manuel Cozar

6

1 reference

20 May 2018

Victoria Adams

7

1 reference

20 May 2018

Stephen Ward

8

1 reference

20 May 2018

Teresa Cabrera

9

1 reference

20 May 2018

Francisco Ruiz-Cabello

10

1 reference

20 May 2018

Natalia Aptsiauri

12

1 reference

20 May 2018

publication date

26 November 2015

1 reference

20 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

20 May 2018

volume

65

1 reference

20 May 2018

issue

1

1 reference

20 May 2018

page(s)

47-59

1 reference

20 May 2018

https://scigraph.springernature.com/pub.10.1007/s00262-015-1774-5

exact match

0 references

cites work

Natural history of HLA expression during tumour development.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

NLRC5: a key regulator of MHC class I-dependent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Targeting HLA class I expression to increase tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Molecular characterization of defective antigen processing in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

MHC antigens and tumor escape from immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Immune selective pressure and HLA class I antigen defects in malignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Changes in beta-2 microglobulin expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

In situ expression of transforming growth factor ?? is associated with melanoma progression and correlates with Ki67, HLA-DR and ?? 3 integrin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1774-5

10.1007/S00262-015-1774-5

21 January 2018

Identifiers

DOI

1 reference

20 May 2018

release_jybcleza7vbt7kgksb7guyldcy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jybcleza7vbt7kgksb7guyldcy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

26611618

1 reference

20 May 2018